Glaukos (NYSE:GKOS) Director Gilbert Kliman Sells 2,500 Shares of Stock

Key Points

• Insider sale: Director Gilbert Kliman sold 2,500 Glaukos shares for $475,000, reducing his holdings by 6.26% to 37,406 shares.
• Strong operating momentum: Glaukos reported quarterly revenue of $185.61 million, up 49.6% year over year, and exceeded analysts’ earnings expectations. However, the company remains unprofitable and is expected to post a full-year loss.
• Analyst sentiment remains positive: Multiple firms raised their price targets, with Glaukos carrying a “Moderate Buy” consensus rating and an average target of $178.08, despite the stock trading near its 52-week high.

Glaukos Corporation (NYSE:GKOS - Get Free Report) Director Gilbert Kliman sold 2,500 shares of Glaukos stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $190.00, for a total transaction of $475,000.00. Following the completion of the sale, the director owned 37,406 shares in the company, valued at approximately $7,107,140. This trade represents a 6.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Glaukos Price Performance

Shares of GKOS traded down $4.30 during mid-day trading on Thursday, hitting $185.25. 791,869 shares of the company were exchanged, compared to its average volume of 942,762. Glaukos Corporation has a 1-year low of $73.16 and a 1-year high of $191.62. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.46 and a current ratio of 5.04. The company has a 50 day moving average of $156.20 and a 200-day moving average of $131.24. The stock has a market cap of $10.93 billion, a price-to-earnings ratio of -57.00 and a beta of 0.78.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.07. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.37%. The firm had revenue of $185.61 million for the quarter, compared to analyst estimates of $150.93 million. During the same period last year, the company posted ($0.24) EPS. Glaukos's quarterly revenue was up 49.6% compared to the same quarter last year. Analysts expect that Glaukos Corporation will post -0.35 EPS for the current fiscal year.

Institutional Trading of Glaukos

A number of large investors have recently modified their holdings of GKOS. First Horizon Corp grew its stake in Glaukos by 1,715.4% during the 4th quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier's stock worth $27,000 after purchasing an additional 223 shares in the last quarter. Allworth Financial LP purchased a new stake in Glaukos during the 2nd quarter worth about $28,000. Los Angeles Capital Management LLC acquired a new stake in Glaukos in the 4th quarter valued at about $28,000. Larson Financial Group LLC boosted its stake in shares of Glaukos by 62.0% in the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier's stock valued at $39,000 after buying an additional 132 shares during the period. Finally, Parallel Advisors LLC boosted its stake in shares of Glaukos by 159.2% in the 1st quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier's stock valued at $40,000 after buying an additional 226 shares during the period. Hedge funds and other institutional investors own 99.04% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Stifel Nicolaus increased their price objective on Glaukos from $175.00 to $190.00 and gave the company a "buy" rating in a research note on Thursday, July 30th. UBS Group assumed coverage on Glaukos in a research report on Tuesday, July 28th. They issued a "neutral" rating and a $150.00 target price on the stock. Wall Street Zen upgraded Glaukos from a "hold" rating to a "buy" rating in a report on Saturday, August 1st. JPMorgan Chase & Co. raised their price objective on Glaukos from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Thursday, April 30th. Finally, Truist Financial upped their target price on shares of Glaukos from $180.00 to $215.00 and gave the company a "buy" rating in a research report on Thursday, July 30th. Twelve analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $178.08.

Glaukos News Summary

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Higher analyst price target: BTIG Research raised its target for Glaukos from $193 to $202 and reiterated a “Buy” rating, citing additional potential upside for the shares. Benzinga
• Positive Sentiment: Strong product momentum: Glaukos’ iDose TR glaucoma implant and Epioxa corneal treatment launch are driving record growth, supporting higher 2026 guidance and expanding the company’s ophthalmology platform. The catalysts have helped the stock gain roughly 67% year to date. GKOS Stock Surges 67% Year to Date: What’s Driving the Rally?
• Positive Sentiment: Improving earnings outlook: Zacks Research raised its FY2027 EPS forecast to $0.45 from $0.38 and its FY2028 estimate to $1.70 from $1.56. It also increased several quarterly estimates, signaling expectations for accelerating profitability as newer products gain adoption.
• Neutral Sentiment: Investor-relations event: Management will participate in the Wells Fargo Healthcare Conference on September 9, which could provide updates on iDose TR, Epioxa, guidance and the development pipeline. Glaukos Announces Participation in Wells Fargo Healthcare Conference
• Negative Sentiment: Near-term profitability remains limited: Glaukos is still expected to post a loss for the current fiscal year, and Zacks modestly reduced its Q2 2027 EPS estimate to $0.06 from $0.07. After the sharp rally, these factors may encourage investors to lock in gains and question the stock’s valuation.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company's core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos's flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source